Shanghai MicroPort MedBot (2252) Announces Updated Remuneration and Appraisal Committee Terms

Bulletin Express
2025/11/25

Shanghai MicroPort MedBot (Group) Co., Ltd. (2252) has published a set of updated terms of reference for its Remuneration and Appraisal Committee. The document emphasizes the Committee’s accountability to the board of directors and outlines how it will formulate and review policies related to remuneration, appraisal, and performance assessments of directors, supervisors, and senior management.

According to the announcement, the Committee will consist of at least three directors, with a majority comprising independent non-executive directors. Its responsibilities cover determining remuneration packages for executive directors and senior management, recommending remuneration for non-executive directors and supervisors, and reviewing performance-based incentives in line with corporate objectives. Furthermore, the document states that any compensation arising from the loss or termination of office must remain fair, consistent with contractual terms, and subject to thorough review.

The updated terms of reference detail a decision-making process that begins with relevant departments providing major financial indicators, operational objectives, and performance data. This information serves as input for the Committee’s annual evaluation, during which directors and senior management present work reports and self-assessments. Based on the findings, proposals for remuneration and incentives are then submitted to the board for review.

The Committee is authorized to seek external professional advice if necessary, with related costs borne by the Company. Additionally, the release highlights confidentiality requirements for all members regarding information discussed at meetings. The new terms become effective upon approval by the board, superseding any previous guidelines governing the Remuneration and Appraisal Committee.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10